Doctor Announces New Advances in the Treatment of Peyronie's Disease

Share Article

A new treatment against one of the most common male sexual disorders.

Dr. George Carroll, specializing in the diagnosis and treatment of male sexual dysfunction for over fifteen years, is pleased to announce that preliminary studies using eletromotive drug administration (EMDA) have demonstrated encouraging results in the treatment of Peyronie's Disease. Dr. Carroll has found that the use of EMDA is especially effective in the treatment of the early stages of this pathology.

Peyronie's Desease is among the most common and most frustrating male sexual disorders. Described as early as the mid-18th century by a French physician, Francois Gigot de la Peyronie, it is an acquired inflammation that sometimes severely impacts a man's sexual performance. Peyronie's Disease consists in the formation of a plaque or hardened scar tissue beneath the skin of the penis. This scarring is non-cancerous, but often leads to painful erections and curvature of the erect penis. Some patients may even develop a plaque that goes all the way around the penis, causing a "waisting" or "bottleneck" deformity of the penile shaft. The majority of patients complain of generalized shrinkage or shortening of their penis. The cause of Peyronie's disease is not certain, though there is often a history of penile trauma. Peyronies's Disease does not cause major health problems and is not life threatening; yet it is distressing to many individuals: frequently there is pain, abnormal curvature of the penis, decreased penile rigidity,difficulty with penetration, and discomfort to both partners during intercourse.

Peyronie's Disease affects a reported 3 to 4 percent of males between ages 40 and 70; some severe cases have been reported in younger men. Medical researchers believe the actual prevalence may be higher (up to about 8% of the US male population), due to patient embarrassment and limited reporting by physicians. There are various degrees of Peyronie's Disease and the majority of cases can be treated, especially in early stages.

According to Urology Channel (http://www.urologychannel.com/peyronies/index.shtml ), EMDA is a painless method of delivering medication to localized tissue using electrical current. Low-level electric current is used to accelerate drugs through the skin to underlying tissues. This process significantly increases the rate of drug administration thereby softening and dissolving the plaque. EMDA delivery of drugs for Peyronie's disease is clinically safe, effective, and non-invasive. Patients realize distinct advantages such as in-home, painless treatment; even distribution of drug in affected tissue; no risk of infection; minimal risk of systemic side effects.

Previous studies have shown that EMDA treatment produces the following effects:

o    Plaque volume reduced - 74% of patients

o    Plaque volume halved - 66% of patients

o    Penile deviation reduced - 74% of patients

o    Pain eliminated - 88% of patients

Two drugs are routinely used to soften and decrease the plaque causing the abnormal curvature. The transdermal EMDA administration of verapamil and dexamethasone is clinically safe and appears to be an effective treatment in patients with Peyronie's disease. Preliminary results being developed and documented by Dr. Carroll (http://www.treatpeyronies.com) using a panel of 24 patients treated in Dr. Carroll's office shows that:

o    42% of patients lost at least 50% of their curvature

o    53% lost at least 40% or more of their curvature

o    95% saw a decrease in curve ranging from a low of 13% decrease to a high of 100% decrease

According to Dr. Carroll "EMDA is the best initial option available today for the treatment of Peyronie Disease. Last year we began using a new EMDA / Verapamil/ SomaCorrrect protocol after published studies indicated that 76% of patients showed significant improvement with documented results. These are encouraging preliminary results, but we need larger numbers of patients and physicians willing to participate in further investigation." Dr. Carroll is an affiliate member of the American Urological Association, an active member of the International Society for Impotence Research and the Sexual Medicine Society of North America. Dr. Carroll's studies were conducted using the Physionizer Mini 2.0, manufactured by Physion, an Italian medical device company.

Physion has patented the EMDA (Electro Motive Drug Administration) technology for drug delivery. Physion's EMDA uses low current electrical stimuli to promote the trans-dermal delivery of drugs. PHYSION is committed to the development of medical devices for use in the field of urology since 1993.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

DANIELA PUGLIELLI

908 212 7846
Email >
Visit website